Targeting Translation of mRNA as a Therapeutic Strategy in Cancer

Translation control of the immune checkpoint in cancer and its therapeutic targeting

(2019) Yichen Xu et al.   NATURE MEDICINE

Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia

(2019) Rong Chen et al.   LEUKEMIA

Inhibitors of nuclear transport

(2019) David A Jans et al.   CURRENT OPINION IN CELL BIOLOGY

Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma

(2018) Ujjawal H. Gandhi et al.   Clinical Lymphoma Myeloma & Leukemia

Karyopherins in cancer

(2018) Tolga Çağatay et al.   CURRENT OPINION IN CELL BIOLOGY

Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation

(2018) Janet L. Oblinger et al.   EXPERIMENTAL NEUROLOGY

Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial

(2018) Weiguo Zhang et al.   HAEMATOLOGICA

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma

(2018) Dan T. Vogl et al.   JOURNAL OF CLINICAL ONCOLOGY

Structure-based Design of Pyridone–Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition

(2018) Siegfried H. Reich et al.   JOURNAL OF MEDICINAL CHEMISTRY

Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial

(2018) Weiguo Zhang et al.   HAEMATOLOGICA

Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma

(2018) Michaël Cerezo et al.   NATURE MEDICINE

Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia

(2018) Karen A. Urtishak et al.   ONCOGENE

Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus-associated oropharyngeal squamous cell cancer

(2017) Lara A. Dunn et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Functional 5′ UTR mRNA structures in eukaryotic translation regulation and how to find them

(2017) Kathrin Leppek et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma

(2017) Salomon Manier et al.   Science Translational Medicine

Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin

(2017) Manoj Garg et al.   Scientific Reports

TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia

(2016) Irene M. Ghobrial et al.   AMERICAN JOURNAL OF HEMATOLOGY

Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies

(2016) Changchun Deng et al.   BLOOD

4EBP1/c-MYC/PUMA and NF- B/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells

(2016) S. Yun et al.   BLOOD

Silvestrol induces early autophagy and apoptosis in human melanoma cells

(2016) Wei-Lun Chen et al.   BMC CANCER

Ribosome Footprint Profiling of Translation throughout the Genome

(2016) Nicholas T. Ingolia   CELL

XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase II  to the Nucleus

(2016) P. Ranganathan et al.   CLINICAL CANCER RESEARCH

Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma

(2016) Mrinal M. Gounder et al.   JOURNAL OF CLINICAL ONCOLOGY

Rocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor

(2016) Shintaro Iwasaki et al.   NATURE

Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia

(2016) S. S. Y. Lam et al.   Science Translational Medicine

Inhibition of nasopharyngeal carcinoma cell proliferation and synergism of cisplatin with silvestrol and episilvestrol isolated from Aglaia stellatopilosa

(2016) MAELINDA DAKER et al.   Experimental and Therapeutic Medicine

Icariside II, a natural mTOR inhibitor, disrupts aberrant energy homeostasis via suppressing mTORC1-4E-BP1 axis in sarcoma cells

(2016) Chao Zhang et al.   Oncotarget

MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study

(2015) C. Copie-Bergman et al.   BLOOD

Differential Requirements for eIF4E Dose in Normal Development and Cancer

(2015) Morgan L. Truitt et al.   CELL

Inhibition of Mitogen-activated Protein Kinase (MAPK)-interacting Kinase (MNK) Preferentially Affects Translation of mRNAs Containing Both a 5′-Terminal Cap and Hairpin

(2015) Nadejda L. Korneeva et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies

(2015) E Hessmann et al.   ONCOGENE

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma

(2015) Brian A. Walker et al.   Nature Communications

KPT-330 has antitumour activity against non-small cell lung cancer

(2014) H Sun et al.   BRITISH JOURNAL OF CANCER

Ribosome Profiling Reveals a Cell-Type-Specific Translational Landscape in Brain Tumors

(2014) C. Gonzalez et al.   JOURNAL OF NEUROSCIENCE

Proteins associated with pancreatic cancer survival in patients with resectable pancreatic ductal adenocarcinoma

(2014) Ru Chen et al.   LABORATORY INVESTIGATION

Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma

(2014) M Affer et al.   LEUKEMIA

Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors

(2014) H. Jean Khoury et al.   LEUKEMIA & LYMPHOMA

RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer

(2014) Andrew L. Wolfe et al.   NATURE

Novel Small Molecule XPO1/CRM1 Inhibitors Induce Nuclear Accumulation of TP53, Phosphorylated MAPK and Apoptosis in Human Melanoma Cells

(2014) Jennifer Yang et al.   PLoS One

Atomic basis of CRM1-cargo recognition, release and inhibition

(2014) Ho Yee Joyce Fung et al.   SEMINARS IN CANCER BIOLOGY

Second-generation derivatives of the eukaryotic translation initiation inhibitor pateamine A targeting eIF4A as potential anticancer agents

(2013) Woon-Kai Low et al.   BIOORGANIC & MEDICINAL CHEMISTRY

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

(2013) S. Hu et al.   BLOOD

Casein Kinase 1  Promotes Cell Proliferation by Regulating mRNA Translation

(2013) S. Shin et al.   CANCER RESEARCH

Identification of drug candidate against prostate cancer from the aspect of somatic cell reprogramming

(2013) Takeo Kosaka et al.   CANCER SCIENCE

Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial

(2013) Jie Jin et al.   LANCET ONCOLOGY

Therapeutic Potential of the Translation Inhibitor Silvestrol in Hepatocellular Cancer

(2013) Takayuki Kogure et al.   PLoS One

Pharmacological targeting of eIF4E in primary CLL lymphocytes

(2013) V Martinez-Marignac et al.   Blood Cancer Journal

MYC, Metabolism, Cell Growth, and Tumorigenesis

(2013) C. V. Dang   Cold Spring Harbor Perspectives in Medicine

Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

(2012) Tina Marie Green et al.   JOURNAL OF CLINICAL ONCOLOGY

Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

(2012) Nathalie A. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

NESdb: a database of NES-containing CRM1 cargoes

(2012) Darui Xu et al.   MOLECULAR BIOLOGY OF THE CELL

The translational landscape of mTOR signalling steers cancer initiation and metastasis

(2012) Andrew C. Hsieh et al.   NATURE

Transient structure and dynamics in the disordered c-Myc transactivation domain affect Bin1 binding

(2012) Cecilia Andresen et al.   NUCLEIC ACIDS RESEARCH

The Oncogene eIF4E Reprograms the Nuclear Pore Complex to Promote mRNA Export and Oncogenic Transformation

(2012) Biljana Culjkovic-Kraljacic et al.   Cell Reports

Resistance to the Translation Initiation Inhibitor Silvestrol is Mediated by ABCB1/P-Glycoprotein Overexpression in Acute Lymphoblastic Leukemia Cells

(2011) Sneha V. Gupta et al.   AAPS Journal

Omacetaxine as an Anticancer Therapeutic: What is Old is New Again

(2011) Meir Wetzler et al.   CURRENT PHARMACEUTICAL DESIGN

Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001

(2011) Sung-Hsin Kuo et al.   EUROPEAN JOURNAL OF CANCER

Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens

(2011) B C Kraljacic et al.   LEUKEMIA

Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma

(2011) W-J Chng et al.   LEUKEMIA

Rearrangement ofMYCIs Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab

(2010) Sharon Barrans et al.   JOURNAL OF CLINICAL ONCOLOGY

Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?

(2010) Katherine L. B. Borden et al.   LEUKEMIA & LYMPHOMA

Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia

(2009) Jiazhuo Liu et al.   AMERICAN JOURNAL OF HEMATOLOGY

The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo

(2009) David M. Lucas et al.   BLOOD

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

(2009) K. J. Savage et al.   BLOOD

Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin

(2009) S. Assouline et al.   BLOOD

Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009

(2009) Alfonso Quintás-Cardama et al.   CANCER

Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells

(2009) Regina Cencic et al.   LEUKEMIA RESEARCH

Potent in vitro and in vivo anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A

(2009) G. Kuznetsov et al.   MOLECULAR CANCER THERAPEUTICS

Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol

(2009) Regina Cencic et al.   PLoS One

Original Research: Intravenous Ribavirin—Review of the FDA's Emergency Investigational New Drug Database (1997–2008) and Literature Review

(2009) Andrea Riner et al.   POSTGRADUATE MEDICINE

Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model

(2008) Marie-Eve Bordeleau et al.   JOURNAL OF CLINICAL INVESTIGATION